Clinical observation of active immunotherapy combined HCG in treatment of unexplained habitual abortion
Ling Liu
Abstract
Ling Liu
Abstract
Objective: To disscuss the clinical effect of unexplained habitual abortion (UHA) with active immunotherapy and human chorionic gonodotropin (HCG) on the patients with UHA. Methods: 118 patients with UHA were randomly divided into experiment group and control group, 87 cases of experiment group were treated with active immunotherapy combined HCG Injection; while other 31 cases of control group were treated with single HCG Injection. Results: The pregnant rate of the treatment group was 86% and 26% in the control group, there was a significant difference between the two groups (P0.05). Conclusion: It is an effective method in treatment of UHA by active immunotherapy and HCG, which is worth further widespread application in clinical treatment of UHA.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Objective: To disscuss the clinical effect of unexplained habitual abortion (UHA) with active immunotherapy and human chorionic gonodotropin (HCG) on the patients with UHA. Methods: 118 patients with UHA were randomly divided into experiment group and control group, 87 cases of experiment group were treated with active immunotherapy combined HCG Injection; while other 31 cases of control group were treated with single HCG Injection. Results: The pregnant rate of the treatment group was 86% and 26% in the control group, there was a significant difference between the two groups (P0.05). Conclusion: It is an effective method in treatment of UHA by active immunotherapy and HCG, which is worth further widespread application in clinical treatment of UHA.
Key concepts: Medicine, Active immunotherapy, Abortion, Immunotherapy, Treatment and control groups, Gynecology, Obstetrics, Pregnancy